AnaptysBio (ANAB) News Today $18.65 +0.46 (+2.53%) Closing price 04:00 PM EasternExtended Trading$17.76 -0.90 (-4.80%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period AnaptysBio could have positive read from J&J abstracts, says GuggenheimMarch 27 at 3:57 PM | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Shares Down 4.1% - What's Next?AnaptysBio (NASDAQ:ANAB) Shares Down 4.1% - What's Next?March 26 at 3:17 PM | marketbeat.comAnaptysBio authorizes $75 million stock buyback planMarch 26 at 7:24 AM | investing.comAnaptysBio Announces $75 Mln Stock Repurchase PlanMarch 26 at 7:24 AM | nasdaq.comAnaptysBio sees cash runway through year-end 2027March 26 at 7:24 AM | markets.businessinsider.comAnaptysBio board authorizes $75M stock repurchase planMarch 26 at 7:24 AM | markets.businessinsider.comShare Buyback Plan Approved by AnaptysBio (NASDAQ:ANAB) Board March 26 at 1:17 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) to Buyback $75.00 million in Stock AnaptysBio (NASDAQ:ANAB - Get Free Report) announced that its Board of Directors has authorized a stock repurchase program on Monday, March 24th, RTT News reports. The company plans to buyback $75.00 million in shares. This buyback authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its shares are undervalued.March 25 at 10:03 PM | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - What's Next?AnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's What HappenedMarch 25 at 11:40 AM | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives $35.11 Average PT from BrokeragesMarch 25 at 1:52 AM | americanbankingnews.comAnaptysBio, Inc.: Anaptys Announces Stock Repurchase PlanMarch 24 at 11:59 PM | finanznachrichten.deAnaptysBio Shares Jump on Buyback Program AuthorizationMarch 24 at 11:59 PM | marketwatch.comAnaptysBio stock rises following stock repurchase planMarch 24 at 11:59 PM | investing.comAnaptys Announces Stock Repurchase PlanMarch 24 at 9:15 AM | globenewswire.comHead-To-Head Contrast: Silo Pharma (NASDAQ:SILO) & AnaptysBio (NASDAQ:ANAB)March 23, 2025 | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from AnalystsAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation andMarch 22, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading 4.4% Higher - Here's WhyAnaptysBio (NASDAQ:ANAB) Stock Price Up 4.4% - Should You Buy?March 21, 2025 | marketbeat.comVictory Capital Management Inc. Purchases 97,200 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Victory Capital Management Inc. lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 41.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 334,450 shares of the biotecMarch 16, 2025 | marketbeat.comAnaptysBio: A Shadow Of Its Former SelfMarch 6, 2025 | seekingalpha.comAnaptysBio (NASDAQ:ANAB) Given New $42.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday.March 6, 2025 | marketbeat.comAnaptysBio price target raised to $42 from $36 at JPMorganMarch 5, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB)HC Wainwright restated a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a research note on Tuesday.March 4, 2025 | marketbeat.comY Intercept Hong Kong Ltd Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)Y Intercept Hong Kong Ltd purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 23,497 shares of the biotecMarch 4, 2025 | marketbeat.comAnaptysBio price target raised to $52 from $36 at GuggenheimMarch 3, 2025 | markets.businessinsider.comLeerink Partnrs Forecasts AnaptysBio FY2029 EarningsAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings estimates for AnaptysBio in a report released on Thursday, February 27th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earnings per shaMarch 3, 2025 | marketbeat.comAnaptysBio (ANAB) Expected to Announce Earnings on MondayAnaptysBio (NASDAQ:ANAB) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Sees Large Growth in Short InterestAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 9,310,000 shares, a growth of 54.4% from the January 31st total of 6,030,000 shares. Based on an average daily volume of 932,600 shares, the days-to-cover ratio is presently 10.0 days.March 2, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up on Earnings BeatAnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Earnings BeatMarch 1, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Issues Earnings ResultsAnaptysBio (NASDAQ:ANAB - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%.February 28, 2025 | marketbeat.comAnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 28, 2025 | finanznachrichten.deAnaptysBio reports Q4 EPS (72c), consensus ($1.70)February 27, 2025 | markets.businessinsider.comAnaptys Announces Participation in March Investor ConferencesFebruary 27, 2025 | globenewswire.comAnaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | globenewswire.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% - Here's WhyAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% - Here's WhyFebruary 19, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Short Interest UpdateAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a decrease of 8.6% from the January 15th total of 6,600,000 shares. Approximately 23.3% of the shares of the company are short sold. Based on an average daily trading volume, of 662,000 shares, the days-to-cover ratio is currently 9.1 days.February 17, 2025 | marketbeat.comQ1 Earnings Estimate for AnaptysBio Issued By HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for AnaptysBio in a report released on Wednesday, February 12th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($1.56) per share for tFebruary 17, 2025 | marketbeat.comWells Fargo & Company Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock PriceWells Fargo & Company boosted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday.February 14, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5% - Still a Buy?AnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5% - Should You Buy?February 13, 2025 | marketbeat.comAnaptysBio price target raised to $51 from $40 at Wells FargoFebruary 13, 2025 | markets.businessinsider.comH.C. Wainwright lifts AnaptysBio stock target to $22, keeps NeutralFebruary 13, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating from WedbushWedbush reaffirmed an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Wednesday.February 13, 2025 | marketbeat.comRosnilimab shows promise in rheumatoid arthritis trialFebruary 13, 2025 | msn.comAnaptysBio stock soars on positive RA trial resultsFebruary 13, 2025 | investing.comTruist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA dataFebruary 13, 2025 | markets.businessinsider.comAnaptysBio price target raised to $22 from $19 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comAnaptys surges as arthritis therapy succeeds in mid-stage trialFebruary 13, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Given Outperform Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday.February 12, 2025 | marketbeat.comAnaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 MonthsFebruary 12, 2025 | globenewswire.comAnaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025February 11, 2025 | globenewswire.comWedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)February 7, 2025 | markets.businessinsider.com Remove Ads Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.680.78▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼185▲ANAB Articles Average Week Remove Ads Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Edgewise Therapeutics News Today Centessa Pharmaceuticals News Today Kymera Therapeutics News Today CG Oncology News Today Denali Therapeutics News Today Belite Bio News Today Arrowhead Pharmaceuticals News Today Arcutis Biotherapeutics News Today Tarsus Pharmaceuticals News Today Harmony Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
